摘要
目的探讨纳武利尤单抗致免疫性肝损伤的临床特点和防治原则。方法回顾1例非小细胞肺癌患者接受肿瘤免疫治疗过程中的病程变化,结合纳武利尤单抗的临床研究、免疫相关不良反应的诊治规范,对本案例进行分析。结果纳武利尤单抗导致了患者出现免疫性肝损伤。在停药予以对症处理后,患者预后良好。结论在抗肿瘤免疫治疗的过程中,需要防范免疫相关不良反应,保证用药安全性和有效性。
OBJECTIVE To explore the clinical characteristics and treatment principles of immune liver injury induced by nivolumab.METHODS Immune liver injury induced by nivolumab was occurred in a case with non-small cell lung cancer,which was analyzed retrospectively combining with the clinical study of nivolumab and the diagnosis and treatment norms of immune-related adverse reactions(irAEs).RESULTS The patientwas occurred immune liver injury induced by Nivolumab.After withdrawal of nivolumaband symptomatic treatment,the patientrecovered.CONCLUSION It is necessary to guard against immune-related adverse reactions during immunotherapy to ensure the safety and effectiveness of drug use.
作者
周守宁
何玉文
谢晓鸿
周承志
ZHOU Shouning;HE Yuwen;XIE Xiaohong;ZHOU Chengzhi(Department of Pharmacy,The First Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong 510120,China;Guangzhou Institute of Respiratory Health,The First Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong 510120,China)
出处
《今日药学》
CAS
2021年第4期318-320,共3页
Pharmacy Today
基金
广东省医学科学技术研究基金(A2020413)。
